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NOT IN MY MAKEUP: THE NEED FOR ENHANCED
PREMARKET REGULATORY AUTHORITY OVER
COSMETICS IN LIGHT OF INCREASED USAGE OF
ENGINEERED NANOPARTICLES
Donald R. Johnson*
1. INTRODUCTION
Consumer products containing nanotechnology are appearing in the
marketplace at an ever increasing rate. This seems to indicate that nothing
short of a scientific revolution is taking place on the nanoscale.1 Cosmetics
comprise a significant market share of the consumer products that are known
to contain nanomaterials.2  However, despite the rapid increase in
nanoparticle usage in cosmetics and other consumer products, scientists have
only recently started examining the potential health and environmental
effects of exposure to these particles. Studies are beginning to show that
nanoparticles possess the ability to penetrate the human body's defenses and
persist in the environment.3 Due to the uncertainty about the health effects
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1. Jessica K. Fender, The FDA and Nano: Big Problems With Tiny Technology, 83
CHi-KENT L. REv. 1063, 1063 (2008) ("We are in the midst of a nanotechnology
revolution. Our understanding of the world changed drastically with the advent of
quantum mechanics, when scientists discovered that contrary to the rules of classical
physics, matter took on novel and unexpected properties when observed at the
nanoscale.").
2. Id. at 1074.
3. See infra Parts Ill.A, C.
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of nanomaterials, even the nanotechnology industry has called for more
toxicology research in this area.
4
Further complicating matters, the United States Food and Drug
Administration (FDA) possesses only minimal regulatory authority over
cosmetics. 5  Most regulatory activity occurs through the Personal Care
Products Council, a voluntary initiative designed by the cosmetics industry
itself.6  Despite the increasing use of nanomaterials, their effects remain
largely untested and cosmetic manufacturers have failed to conduct testing
to substantiate the safety of products containing nanomaterials.
Manufacturers do not label products containing these materials with
warnings about the lack of safety substantiation. In fact, companies are not
even required by the FDA to inform the consumer of the presence of
4. See Robert F. Service, Calls Rise for More Research on Toxicology of
Nanomaterials, 310 SCIENCE 1609, 1609 (2005).
5. See Fender, supra note 1, at 1074.
6. This Note focuses solely on the FDA's regulatory authority and procedures, but
the self-regulating nature of the cosmetics industry is a source of both praise and
criticism. See Peter Baron Hutt, A History of Government Regulation ofAdulteration and
Misbranding of Cosmetics, in COSMETIC REGULATION IN A COMPETITIVE ENVIRONMENT 1,
29 (Norman F. Estrin & James M. Akerson eds., 2000). Hutt states:
No industry in the history of this country has ever made a greater commitment
to self-regulation or has been more successful in achieving it than the U.S.
cosmetic industry. Virtually all aspects of the cosmetic industry are subject to
some form of voluntary CTFA program initiated by the industry itself to assure
FDA, the medical profession, and the public that cosmetic products are safe and
appropriately labeled.
Id. at 1. See also Thaddeus Herrick, Amid Health Concern, Nail-Polish Makers Switch
Formulas, WALL ST. J., Apr. 19, 2004, at B 1. Ken Cook, President of the Environmental
Working Group, noted that the cosmetic industry's self-regulating structure offers little
protection to consumers and further stated, "[i]t's not just the fox guarding the henhouse.
It's the fox designing and building the henhouse." Thaddeus Herrick, Amid Health
Concern, Nail-Polish Makers Switch Formulas, WALL ST. J., Apr. 19, 2004, at B1. For
further information about the industry-created voluntary regulatory system, see generally
Gerald N. McEwan, et al., Voluntary Self-Regulation: A Case Study, in COSMETIC
REGULATION IN A COMPETITIVE ENVIRONMENT 185 (Norman F. Estrin and James M.
Akerson eds., 2000).
7. See Government Accountability Office, Cosmetics Regulation: Information on
Voluntary Actions Agreed to by FDA and the Industry, HRD-90-58, 4 (1990), available
at http://archive.gao.gov/d24t8/141081.pdf [hereinafter GAO Report 1].
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nanomaterials. 8 An Environmental Working Group study of the Cosmetic
Ingredient Review,9 an industry-funded panel of experts whose mandate is to
conduct safety assessments of cosmetic products, found that the panel had
reviewed only eleven percent of the 10,500 ingredients used in cosmetic
products and had fully assessed only twenty-eight of 7,500 cosmetic
products.' 0 These failings have put consumers in the United States at an
unacceptable risk and have strengthened the call for increased regulation of
cosmetic products.
As studies continue to weigh the benefits and risks of nanotechnology, the
debate over what constitutes appropriate regulation has raged among
industry and regulatory officials, elected leaders, and consumer groups,
though all agree that there should be further assessment of the risk to human
health and the environment posed by nanomaterials. I I Opinions vary widely
from a strict laissez-faire approach to a complete ban on all nanotechnology-
8. See infra note 186.
9. For a comprehensive discussion of the Cosmetic Ingredient Review, see
generally Wilma F. Bergfeld & F. Allan Andersen, The Cosmetic Ingredient Review, in
COSMETIC REGULATION IN A COMPETITIVE ENVIRONMENT 195 (Norman F. Estrin and
James M. Akerson eds., 2000). See also Cosmetic Ingredient Review, How Does CIR
Work?, http://www.cir-safety.org/info.shtml (last visited Oct. 1, 2009).
10. Environmental Working Group Cosmetics Petition, FDA Citizen's Petition
Docket No. 2006P-0266/CP 1, 2 (June 2004), available at http://www.fda.gov/
ohrns/dockets/dailys/04/June04/061704/04p-0266-cpOOOO1-01-vol 1 .pdf.
1I. See generally Service, supra note 4; see also Environmental and Safety Impacts
of Nanotechnology: What Research Is Needed: Hearing Before the H. Comm. on Sci. and
Tech., 109th Cong. 6-7 (2005). Organizations as diverse as environmental NGOs
[nongovernmental organizations], large chemical companies, nanotech start-ups,
insurance companies, and investment firms all agree that the federal government should
be immediately directing many more of the dollars it is currently investing in
nanotechnology development toward identifying and assessing the potential risks of
nanomaterials to human health and the environment. Environmental and Safety Impacts
of Nanotechnology: What Research Is Needed: Hearing Before the H. Comm. on Sci. and
Tech., 109th Cong. 6-7, 66 (2005) (Statement of Dr. Richard A. Denison, Senior
Scientist, Environmental Defense); see also Juliet Eilperin, Nanotechnology's Big
Question: Safety, WASH. POST, Oct. 23, 2005, at Al l. "The [FDA]'s decision to approve
the company's plan [to produce a product composed of nanoparticles] comes amid an
ongoing debate among government officials, industry representatives, academics and
environmental advocates over how best to screen the potentially toxic materials." Juliet
Eilperin, Nanotechnology 's Big Question: Safety, WASH. POST, Oct. 23, 2005, at A 11.
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related research and products. 12 Regardless of the many viewpoints, one
thing is certain: nanotechnology is an area in which the FDA must engage
in rapid regulatory adaptation.
This Note discusses the health and environmental risks of nanoparticles,
provides a history of cosmetic regulation, and proposes a legislative solution
that will expand the FDA's regulatory authority over cosmetics while
facilitating industrial progress. Specifically, Part II describes nanoparticles,
their presence in cosmetics, and explains the unique properties which make
them a potential threat to human health and safety. Part III discusses
nanotoxicology, examining how these particles enter and cause damage
within the body, and briefly touches upon nanotoxicity observed in the
environment. Part IV consists of a history of cosmetic regulation, including
failed legislative attempts to expand FDA authority over cosmetics, and an
examination of the FDA's current cosmetics policies. Part V examines the
FDA's current stance on the use of nanoparticles in cosmetics. Finally, Part
VI proposes a legislative solution: granting the FDA expanded regulatory
authority over cosmetics. This will enable the agency to swiftly and
effectively implement a fair regulatory scheme that burdens neither
government nor industry. The expanded regulatory authority will also allow
the FDA to adapt to the rapid rise in nanoparticle-containing cosmetic
products and implement policies to guarantee that the American public is
safe from unnecessary harm.
II. NANOPARTICLES
A. Nanoparticles Generally
Nanoparticles are materials so small that their physicochemical properties
differ from bulk materials of the same composition. 13 They are defined by
ASTM International as ultrafine particles with dimensions greater than one
12. See generally GLENN REYNOLDS, FORWARD TO THE FUTURE: NANOTECHNOLOGY
AND REGULATORY POLICY (Pacific Research Institute 2002) (proposing a laissez-faire
approach to the regulation of nanomaterials), available at http://Iiberty.pacificresearch.
org/docLib/2002Forward to Nanotech.pdf; GARY E. MARCHANT, LESSONS FOR NEW
TECHNOLOGIES, 6-7 (Mercatus Center, George Mason University 2008) ("In July 2007, a
coalition of forty-five public interest groups issued a position statement calling for a ban
on commercialization of any 'untested or unsafe uses of nanomaterials and requiring
product manufacturers and distributors to bear the burden of proof."'), available at
http://www.mercatus.org/uploadedFiles/Mercatus/Publications/WP0826_RSPLessons%
20for/o2ONew%/20Technologies.pdf.
13. C. Medina et al., Nanoparticles: Pharmacological and Toxicological
Significance, 150 BRIT. J. PHARMACOLOGY 552, 552 (2007).
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nanometer (nm) but smaller than 100 nanometers.' 4 To put this size into
context, "[a] single human hair is about 80,000 nm wide, a red blood cell is
approximately 7,000 nm wide and a water molecule is almost 0.3 nm
across.",
15
Nanotechnology has become very attractive for commercial development.
Many different types of industry have found them useful in a broad spectrum
of products ranging from cosmetics to clothing, electronics to aerospace
16technologies. Despite the standard provided by ASTM International, the
definition of what constitutes "nanotechnology" and, as a result,
nanoparticles, remains controversial and unsettled. Though the FDA has not
adopted a formal definition of what constitutes nanotechnology, it did
participate in the formulation of the definition adopted by the National
Nanotechnology Initiative (NNI). Under this definition, something is
nanotechnology if it involves:
Research and technology development at the atomic, molecular or
macromolecular levels, in the length scale of approximately 1 -
100 nanometer range. Creating and using structures, devices and
systems that have novel properties and functions because of their
small and/or intermediate size. Ability to control or manipulate on
the atomic scale.1
7
The FDA essentially adopts this definition by incorporation on its website,
stating that "nanotechnology relevant to the FDA might include research and
14. ASTM International, E 2456-06, Terminology for Nanotechnology 2 (2006).
Originally known as the American Society for Testing and Materials, ASTM
International "is one of the largest voluntary standards development organizations in the
world-a trusted source for technical standards for materials, products, systems, and
services." ASTM International, http://www.astm.org/ABOUT/aboutASTM.html (last
visited Oct. 12, 2009). A nanometer is defined as one billionth of a meter. MERRIAM-
WEBSTER'S COLLEGIATE DICTIONARY 824 (11 th ed. 2003).
15. THE ROYAL SOCIETY AND THE ROYAL ACADEMY OF ENGINEERING, NANOSCIENCE
AND NANOTECHNOLOGIES: OPPORTUNITIES AND UNCERTAINTIES vii (2004), available at
http://www.nanotec.org.uk/report/Nano%20report%202004%20fin.pdf [hereinafter
ROYAL SOCIETY].
16. Id. at viii, 9.
17. EPA, CONCEPT PAPER FOR THE NANOSCALE MATERIALS STEWARDSHIP PROGRAM
UNDER TSCA 10-11 (July 12, 2007), available at http://www.regulations.gov/fdmspublic/
component/main?main=DocumentDetail&d=EPA - H Q - O P P T - 2 0 0 4 - 0 122-0058.
2009 Enhanced Premarket Regulatory Authority over Cosmetics
technology development that both satisfies the NNI definition and relates to
a product regulated by FDA."'
18
The FDA acknowledges that it is aware of products under its purview that
currently contain or claim to contain nanoparticles. 19 One nanotechnology
research group lists over 1,000 products that are currently on the market and
are manufacturer-identified as containing nanotechnology. 20  Over half of
these products are manufactured within the United States2 1 and include
paints, sunscreens, tennis rackets, golf balls, stain resistant clothing, and
cosmetics.22 Due to their broad range of uses, thousands of tons of
nanomaterials are produced each year23 and the demand for nanomaterial-
containing products continues to grow at an enormous rate. According to
IndustryWeek, a report by Lux Research indicates that "[tjhe market for
nanotechnology-based products is expected to reach $3.1 trillion by 2015, up
from $147 billion in 2007.,24 As a result of early projections of this trend,
Congress passed the 21st Century Nanotechnology Research and
18. FDA, SCIENCE & RESEARCH, NANOTECHNOLOGY, FREQUENTLY ASKED
QUEsTIONshttp://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/Freque
ntlyAskedQuestions/default.htm (last visited Oct. 1, 2009) [hereinafter FDA
Nanotechnology FAQs].
19. Id. "FDA is aware of several FDA regulated products that employ
nanotechnology." Id
20. THE WOODROW WILSON INTERNATIONAL CENTER FOR SCHOLARS, PROJECT ON
EMERGING NANOTECHNOLOGIES, NANOTECHNOLOGY CONSUMER PRODUCTS INVENTORY,
http://www.nanotechproject.org/inventories/consumer/ (last visited Oct. 1, 2009)
[hereinafter WILSON CENTER] (database includes 803 manufacturer-identified
nanomaterial consumer products).
21. Id.
22. Rick Weiss, For Now, Consumer Nanotech Concentrates on the Little Things,
WASH. POST, Mar. 10, 2006, at A3; Garry Kranz, Buyer Beware: Product List Highlights
Both Nanotech and Nano-Marketing, SMALL TIMES, March 16, 2006, available at
http://www.smalltimes.com/articles/article_display.cfm?Section=ARCHI&C=Consu&A
RTICLEID=270536&p= 109.
23. ROYAL SOCIETY, supra note 15, at 26-27.
24. Jonathan Katz, Nanotechnology Boom Expected by 2015, INDUSTRYWEEK, July
22, 2008, http://www.industryweek.com/ReadArticle.aspx?ArticlelD = 16884&Section
ID=35.
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25Development Act in 2003. This statute authorized $3.6 billion for several
federal agencies to engage in research and development in nanotechnology
in an effort to ensure the position of the United States at the forefront of this
new and burgeoning field.26
B. Nanoparticles in Cosmetics
Currently, "some of the most prominent nanotechnology products on the
U.S. market are cosmetics," 27 which comprise over fifteen percent of the
market in such products. 28  These cosmetic products include L'Oreal's
RevitaLift Double-Lifting treatment anti-wrinkle cream, which contains Pro-
Retinol A nanosomes 29 and Zelens' name-brand face cream, which contains
C60 molecules30 (also known as buckminsterfullerenes or "buckyballs," but
hereinafter "C60"). During a congressional hearing on nanotechnology, Dr.
Richard A. Denison, Senior Scientist of Environmental Defense, stated that
"[w]e already have nanomaterials of a variety of types in cosmetics, in
dispersive applications that are going to introduce these materials in a fairly
uncontrolled way .... 31 The uncontrolled introduction of this technology
25. 15 U.S.C. §§ 1701-1709 (2006).
26. Id. at § 7505.
27. See Fender, supra note 1, at 1074; see also Tim Little, Sanford Lewis & Pamela
Lundquist, BENEATH THE SKIN: HIDDEN LIABILITIES, MARKET RISK AND DRIVERS OF
CHANGE IN THE COSMETICS AND PERSONAL CARE PRODUCTS INDUSTRY 12 (2007),
available at http://www.iehn.org/filesaitIEl-NCosmeticsReportFin.pdf. "While ques-
tions about the health impact of nanotechnology are certainly broader than the cosmetics
industry, their usage in cosmetics and personal care products represents a source of
concern to investors since cosmetics companies are already deploying nanotechnology in
various applications." Id.
28. See Fender, supra note 1, at 1074.
29. Liesl Schillinger, Smart Enough To Understand Your Moisturizer?, N.Y. TIMES,
Dec. 22, 2005, at G3.
30. WILSON CENTER, supra note 20; Zelens Fullerene C-60 Night Cream,
http://www.nanotechproject.org/inventories/consumer/browse/products/5266/ (last visited
Oct. 1, 2009). The C60 molecule used in this cream is the same molecule that will be later
shown to bind to and deform DNA sequences. Zhao, et al., infra note 93, at 3856.
3 1. Research on Environmental and Safety Impacts of Nanotechnology: Current
Status of Planning and Implementation Under the National Nanotechnology Initiative:
Hearing Before the H. Subcomm. on Research and Science Education of the H. Comm.
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exposes the American people to potentially harmful materials through their
daily use of cosmetic products. Dr. Denison's statement refers to the fact
that nanomaterials used in cosmetics are free nanomaterials that are not fixed
or embedded in another substance 32 and can thus move freely within the
medium into which they are introduced. An example of a free nanomaterial
is titanium dioxide, which is used extensively in cosmetics and sunscreens.33
Despite the use of free nanomaterials in cosmetics, there is still relatively
little research information on skin penetration by nanoparticles34 and "none
of the nanoscale materials currently used in cosmetics has been substantiated
for safety by the FDA ....
The physicochemical properties of nanoparticles require a safety
substantiation process. A thorough explanation of these properties
demonstrates why stricter regulation and labeling requirements is crucial,
particularly for cosmetics.
C. Physicochemical Properties of Nanoparticles
As previously stated, the physicochemical properties of nanoparticles
differ from those of bulk material of the same composition. There are two
on Science and Technology, 110th Cong. 87 (2007) (statement of Richard A. Denison,
Senior Scientist, Environmental Defense).
32. ROYAL SOCIETY, supra note 15, at viii; FRIENDS OF THE EARTH, NANOMATERIALS,
SUNSCREENS AND COSMETICS: SMALL INGREDIENTS, BIG RISKS (May 26, 2006),
nano.foe.org.au/filestore2/download/ 125/FoEA nano cosmetics report web.pdf.
33. Borb~ila Kiss et al., Investigation of micronized titanium dioxide penetration in
human skin xenografts and its effect on cellular functions of human skin-derived cells, 17
EXPERIMENTAL DERMATOLOGY 659, 659 (2008). Nanoparticles used in cosmetics are
free nanoparticles that are not fixed. See Albert C. Lin, Size Matters: Regulating
Nanotechnology, 31 HARV. ENVTL. L. REV. 349, 354 (2007) "Nanomaterials may be
either fixed as integral features of larger objects (as electronic components, for instance),
or used as free nanoparticles (in cosmetics or pharmaceuticals, for example)." Albert C.
Lin, Size Matters: Regulating Nanotechnology, 31 HARV. ENVTL. L. REV. 349, 354
(2007).
34. See Kiss et al., supra note 33, at 660.
35. Transcript of Public Meeting on Nanotechnology Materials in FDA Regulated
Products, Oct. 10, 2006, at 138 (statement by Jane Houlihan, Vice President for
Research, Environmental Working Group), available at http://www.fda.gov/downloads/
ScienceResearch/SpecialTopics/Nanotechnology/NanotechnologyTaskForce/ucm 111446.
pdf.
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primary reasons why nanoparticles are subject to these different properties.
First, nanoparticles are characterized by a large surface area to volume
ratio.36 Second, particles smaller than fifty nm are subject to the laws of
quantum physics and not to the laws of classical physics.37 These unique
characteristics will ultimately contribute to the likelihood of adverse health
effects if stronger regulatory authority is not granted to the FDA. In fact, in
February 2007, the United States Environmental Protection Agency (EPA)
published a white paper on nanotechnology that repeatedly stressed that the
differences between nanoparticles and their macro-scale counterparts posed
a potential threat:
It is important to note that nanomaterials have large surface areas
per unit of volume, as well as novel electronic properties relative
to conventional chemicals. Some of the special properties that
make nanomaterials useful are also properties that may cause some
nanomaterials to pose hazards to humans .... It will be necessary
to consider these unique properties and issues, and their potential
impacts on fate, exposure, and toxicity, in developing risk
assessments for nanomaterials.
38
1. The Significance of Greater Surface Area to Volume Ratio
The unique surface area to volume ratio seen in nanoparticles may serve
to determine reactivity, which is "key to defining the chemical and
biological properties of nanoparticles. 39 Interactions and catalytic reactions
36. Citizen Petition to the United States Food and Drug Administration filed by the
International Center for Technology Assessment, 15-16, available at http://www.icta.org
/doc/Nano%20FDA%20petition%20final.pdf [hereinafter CTA Petition].
37. Id.
38. EPA, NANOTECHNOLOGY WHITE PAPER, EPA 1001B-07/001, 30 (2007),
available at http://www.epa.gov/osa/pdfs/nanotech/epa-nanotechnology-whitepaper-0207
.pdf [hereinafter EPA WHITE PAPER].
39. Andre Nel et al., Toxic Potential of Materials at the Nanolevel, 311 SCIENCE 622,
622-23 (2006) [hereinafter Nel I] (demonstrating the inverse relationship between the
number of surface molecules and particle size).
In the size range <100 nm, the number of surface molecules (expressed as a %
of molecules in the particle) is inversely related to particle size. For instance, in
a particle of 30 nm size, about 10% of its molecules are expressed on the
surface, whereas at 10 and 3 nm size the ratios increase to 20% and 50%,
respectively. Because the number of atoms or molecules on the surface of the
particle may determine the material reactivity, this is key to defining the
chemical and biological properties of nanoparticles.
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40occur on the surfaces of particles. As a result of the increased surface area
that directly exposes large numbers of molecules or atoms, nanoparticles
have an increased potential for biological interaction and may be much more
reactive, thus increasing their intrinsic toxicity.4 1 Part of this toxicity results
from the ability of various nanoparticles to generate free radicals, singlet
oxygen, hydroxyls, and other reactive oxygen species (ROS). 42  These
chemical forms have been observed in laboratory settings both with and
without exposure to light.43 The ability to create ROS without light implies
that the toxicity of nanoparticles can continue even after their penetration
into bodily tissues.
Id. at 623, Fig. 1.
40. DR. CHRISTOPH LAUTERWASSER, SMALL SIZES THAT MATER: OPPORTUNITIES
AND RISKS OF NANOTECHNOLOGIES 10 (Allianz Center for Technology 2007), available at
http://www.allianz.com/static-resources/images-2006-12-13/pdf/saobj_809372_allianz
_studynanotechnologyengl.pdf.
41. Nel I, supra note 39, at 622-23; see also LAUTERWASSER, supra note 40, at 30.
42. Min Chen & Anna von Mikecz, Uptake and Cytotoxicity of Nanoparticles, in
NANOTOXICOLOGY 75, 83-84 (Yuliang Zhao & Hari Singh Nalwa eds., 2007). For an
excellent overview of reactive oxygen species and their toxicological nature, see
generally Barry Halliwell, Reactive Oxygen Species and the Central Nervous System, 59
J. OF NEUROCHEMISTRY 1609 (1992) ("A free radical is defined as any species capable of
independent existence (hence the term 'free') that contains one or more unpaired
electrons."). See also Christopher Wanjek, Mixed Messages - Antioxidants May in Some
Cases Do More Harm Than Good, WASH. POST, Aug. 7, 2001, at HEO. This article
reports:
Free radicals are highly reactive molecules, or single atoms with unpaired
electrons, looking for a mate. So they steal an electron from the first thing they
encounter, perhaps a cell wall or a strand of DNA. As free-radical damage
mounts, cells can no longer perform properly. Tissues degrade. Disease sets in.
An excess of free radicals has been cited in the development of cardiovascular
disease, Alzheimer's disease, Parkinson's disease and cancer. Aging itself has
been defined as a gradual accumulation of free radical damage.
Id.
43. Chen & von Mikecz, supra note 42, at 84.
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2. Altered Physicochemical Properties in Relation to Macro-scale
Counterparts
The effects of reducing materials to the nanoscale are further reaching
than simply making them more compact or refined. Rather, these nanoscale
materials begin to exhibit fundamental properties that are sometimes
radically different from their macro-scale form. These properties include
electrical, optical, magnetic, toxicity, chemical or photo-reactivity, bio-
accumulation, and explosiveness. 44 Some of the changes from macro to
nanoscale are disturbing. At the macro-scale, aluminum is a stable metal;
however, at twenty to thirty nm, aluminum becomes explosive.45 Silicon is
an insulator at macro-scale, but becomes a conductor on the nanoscale.4 6
Another troubling property exhibited by nanoparticles is that they cannot be
viewed with standard optical microscopes because the size of the particles
places them below the diffraction limit of visible light.47 Simply stated,
many "breeds" of nanoparticles are invisible without the aid of expensive
electron microscopes.
Furthermore, the changes that occur when scaling a material down to the
nanoscale are unpredictable. As a National Geographic writer aptly
44. See, e.g., Ernie Hood, Nanotechnology: Looking as We Leap, 112 ENVTL.
HEALTH PERSP. A741 (2004); see also EPA WHITE PAPER, supra note 38, at 34, 36.
45. Jennifer Kahn, Nano's Big Future, NAT'L GEOGRAPHIC, June 2006, at 98, 100,
available at http://ngm.nationalgeographic.com/2006/06/nanotechnology/kahn-text; see
also Jeremy Hsu, New Rocket Fuel Mixes Ice and Metal, SPACE.COM, Oct. 21, 2009,
http://www.space.com/businesstechnology/091021 -tw-alice-rocket.html.
46. Nancy J. Brown, Nanotechnology: Is New Regulation Needed, And If So, By
Whom?, LEGAL BACKGROUNDER, July 25, 2008, at 1, available at http://www.wlf.org
/upload/07-25-08brown.pdf. See also Delara Karkan, Associate Director, Center for
Evaluation of Radiopharmaceuticals, Health Canada, Remarks at the Public Meeting on
Nanotechnology Materials in FDA Regulated Products 39 (Oct. 10, 2006), transcript
available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/Nanotech
nology/NanotechnologyTaskForce/ucm 111 446.pdf.
47. European Commission, Health & Consumer Protection Directorate General
Opinion on The appropriateness of existing methodologies to assess the potential risks
associated with engineered and adventitious products of nanotechnologies, at 18 (Mar.
10, 2006), available at http://ec.europa.eu/health/ph risk/committees/04_scenihr/docs/
scenihr_o_003b.pdf. See also, CIENTIFICA, NANOPARTICLES, TECH. WHITE PAPERS NR. 3 at
6 (Oct. 2003), http://images.iop.org/dlnano/wp/nanoparticlesWP.pdf (explaining that
"the fact that nanoparticles have dimensions below the critical wavelength of light
renders them transparent.").
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described it, "[i]t's like you shrink a cat and keep shrinking it, and then at
some point, all at once, it turns into a dog.' ' 8 Not only are these changes
unpredictable, they occur regardless of the same material's macro-scale
properties. One study concluded, "[e]xperts are overwhelmingly of the
opinion that the adverse effects of nanoparticles cannot be reliably predicted
or derived from the known toxicity of the bulk material., 49 The United
Kingdom Royal Society and the Royal Academy of Engineering (Royal
Society), one of the world's oldest scientific organizations, has repeatedly
emphasized that the toxicity of nanoparticles should not be inferred from
their macro-scale counterparts: "Free particles in the nanometre size range
do raise health, environmental and safety concerns and their toxicology
cannot be inferred from that of particles of the same chemical at a larger
size. ,, 5 1
The unpredictable and potentially toxic changes that occur when a
material is "nanosized" must be further studied before more products
containing nanoparticles are let loose upon the public. One of the leading
uses of nanoparticles is in cosmetic products, which are worn directly on the
body and sometimes even used on or near mucous membranes. 52 Due to
their extensive application directly onto or into the human body, cosmetic
products should, at the very least, be subjected to extensive toxicity testing
before entering into the marketplace. As a newly developing field,
nanotoxicology has begun to demonstrate that the unique properties of
nanoparticles can have deleterious effects on human physiology and the
environment.
III. NANOTOXICOLOGY
The results of toxicological studies conducted with engineered
nanoparticles of the type found in cosmetics are troubling. A report released
in April 2008 shows that nanoparticles have had several adverse effects in
48. Kahn, supra note 45, at 103.
49. LAUTERWASSER, supra note 40, § 6.4, at 30 (emphasis added).
50. The Royal Society, Brief history of the society, http://royalsociety.org/page.
asp?id=2176 (last visited Oct. 19, 2009).
51. ROYAL SOCIETY, supra note 15, at 49 (emphasis added).
52. For example: mascaras, eyeliners, and lipsticks are applied near the mucous
membranes in the eyes and mouth, while foundations, blushes, bronzers, and concealers
are worn directly on the skin of the face.
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toxicology studies done with animals, including nephrotoxicity (causing
kidney damage), adverse effects on the reproductive system, and genotoxic
effects on the animals' DNA.5 3 Some nanoparticles also caused granulomas,
fibrosis, and reactions resembling tumors in the lungs of the test animals. 54
Cellular structural damage and oxidative stress have been observed in both
in vivo and in vitro studies. 55 Studies also "suggest that nanoparticles can
penetrate the body more readily and more deeply than larger particles." 56 As
one author wrote, "a plethora of scientific evidence points to the potential
dangers of nanotechnology products." 57 The following sections will show
that the potential damage caused by nanoparticles is a serious concern that
the FDA cannot continue to ignore by allowing cosmetic products to proceed
to market with no premarket testing or enforcement regulations.
53. CLAUDE OSTIGUY ET AL., LES EFFETS SUR LA SANTE RELIES AUX NANOPARTICULES ii
(2d ed. 2008) ("Chez l'animal, plusieurs effets ont d~jA 6 d~montr6s dont des effets
toxiques au niveau de plusieurs organes (coeur, poumons, reins, syst~me reproducteur...)
de mme que de la gdnotoxicit6 et de la cytotoxicit6. Certaines particules, par exemple,
causent des granulomes, de la fibrose et des r6actions tumorales au niveau pulmonaire.").
54. Id. A granuloma is "a mass or nodule of chronically inflamed tissue with
granulations that is usually associated with an infective process." MERRIAM-WEBSTER'S
COLLEGIATE DICTIONARY 545 (1lth ed. 2003). Fibrosis is "a condition marked by
increase of interstitial fibrous tissue." MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY
465 (11 th ed. 2003).
55. Gunter Oberdorster et al., Principles for Characterizing the Potential Human
Health Effects from Exposoure to Nanomaterials: Elements of a Screening Strategy, 2
PARTICLE & FIBRE ToxICOLOGY § 3.0 (2005), available at http://www.particle
andfibretoxicology.com/content/2/1/8 [hereinafter Oberd6rster 1]; Noreen Parks, New
Nano-Headache?, SCIENCE-Now DAILY NEWS, June 15, 2006, available at
http://sciencenow.sciencemag.org/cgi/content/full/2006/615/I (reporting that even small
concentrations of titanium dioxide nanoparticles can produce damaging free radicals in
mouse brain cells). Studies done in vivo are studies done when nanomaterials are put "in
the living body of a plant or animal." MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY
659 (11th ed. 2003). Studies done in vitro are studies done when the effects of
nanomaterials are studied "outside the living body and in an artificial environment."
MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY 659 (11 th ed. 2003).
56. Lin, supra note 33, at 359 (discussing laboratory testing on animal subjects).
57. Fender, supra note 1, at 1068-69.
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A. Penetration and Absorption of Nanoparticles
The method of penetration and absorption of nanoparticles examined for
the purposes of this Note is dermal penetration. Though nanoparticles can
enter the body by many means, including inhalation and ingestion,
58
cosmetic products are primarily developed for extended contact with the
skin. 59 The skin is the largest organ of the body and is composed of three
layers: the epidermis, the dermis, and the subcutaneous layer." The
outermost layer of the epidermis is the stratum corneum, a strongly
keratinized layer that functions as the skin's primary protector against
outside agents, including microorganisms, chemicals, and allergens.
62
However, in the case of nanoparticles, even unbroken skin is not truly
unbroken. In most mammalian species, which includes humans, up to one
percent of the total skin surface area is made up of sweat glands and hair
follicles.63 The pilot study on dermal penetration found that ten to fifty nm
particles of titanium dioxide could penetrate into the dermis layer despite the
58. Gunter Oberdorster et al., Nanotechnology: An Emerging Discipline Evolving
from Studies of Ultrafine Particles, 113 ENVTL. HEALTH PERSP. 823, 837 (2005)
[hereinafter Oberd6rster II].
59. Yuliang Zhao, et al., Biological Activities of Nanomaterials/Nanoparticles, in
NANOTOXICOLOGY 1, 19 (Yuliang Zhao & Hari Singh Nalwa eds., 2007). "Nowadays,
the main route by which nanoparticles can touch human skin is through the use of
cosmetic products and sunscreens, etc., which involve various nanoparticles as functional
components." Id. See also American Academy of Dermatology, Cosmeceutical Facts &
Your Skin, http://www.aad.org/public/publications/pamphlets/general_cosmeceutical.
html (last visited Oct. 19, 2009) ("It is important to select makeup carefully because it
remains in contact with the skin for a long time.").
60. Zhao et al., supra note 59, at 6.
61. A very illustrative explanation of keratinized tissue is provided by Nanomaterial
Science Lab of National Chung Cheng University in Taiwan,
http://www.nmsl.chem.ccu.edu.tw/tea/SKN 910721.htm (last visited Sept. 30, 2009)
("As skin cells move farther away from their source of nourishment, they flatten and
shrink. They lose their nuclei, move [to the outermost layer of the epidermis], and turn
into a lifeless protein called keratin. After serving a brief protective function, the
keratinocytes are imperceptibly sloughed off.").
62. Id.
63. Id.
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protections of the stratum comeum. Further studies have shown that
rubbing and flexing the skin, common actions in the application and removal
of cosmetic products, results in faster and deeper penetration by
nanoparticles. In addition, dama ed skin allows much larger nanoparticles
to penetrate the skin more readily.
6
Scientific data strongly suggests that once in the dermis or subcutaneous
layer, nanoparticles can translocate, via the lymphatic system, throughout
the body and into vital organ tissue.67 Further, a 2004 study involving mice
and pigs showed that intra-dermally injected nanoparticles will localize in
regional lymph nodes.68  A study conducted with small asbestos fibers
suggests that nanoparticles can also translocate into the bloodstream. 69
Although dermal penetration does not appear to be the most efficient method
of entry for nanoparticles, the call for continued research in this area
v°
demonstrates a legitimate scientific concern with the permeability of the skin
to nanoparticles.
64. Angela Simonelli et al., Interactions Between Nanoparticles and Living
Organisms: Mechanisms and Health Effects, in NANOTOXICOLOGY 29, 39 (Yuliang Zhao
& Hari Singh Nalwa eds., 2007). Further studies demonstrated that the degree of
penetration can be greater as a result of the presence of hair follicles and sweat glands on
human skin. Id.
65. Repetitive Motion Speeds Nanoparticle Uptake: 'Bucky Amino Acid' Penetrates
Faster, Deeper When Skin Is Flexed, SCIENCEDAILY, Jan. 9, 2007,
http://www.sciencedaily.com/releases/2007/01/070104144839.htm; Tinkle et al., Skin as
a Route of Exposure and Sensitization in Chronic Beryllium Disease, 111 ENVTL.
HEALTH PERSP. 1202, 1207 (2003).
66. See Oberdorster 11, supra note 58, at 834.
67. See Simonelli et al., supra note 64, at 40.
68. Id.
69. Id.; see also Milind Kandlikar, et al., Health risk assessment for nanoparticles: A
case for using expert judgment, in NANOTECHNOLOGY AND OCCUPATIONAL HEALTH 135,
146 (Andrew D. Maynard & David Y.H. Pui eds., 2007).
70. UNITED KINGDOM DEPARTMENT FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS,
CHARACTERISING THE POTENTIAL RiSKS POSED BY ENGINEERED NANOPARTICLES, A
SECOND UK GOVERNMENT RESEARCH REPORT 26, 56 (2007), available at
http://www.defra.gov.uk/environment/quality/nanotechldocuments/nanoparticles-
riskreport07.pdf.
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Despite the focus on dermal penetration, one other method by which
nanoparticles move must be briefly examined. A study by researchers with
Japan's National Institute of Health Sciences demonstrated that C60, once in
the bloodstream, passes through the placental barrier and enters into any
developing embryo. 7' Not only did the examined nanoparticles enter the
embryos, they caused severe abnormalities and death.7v  While the idea of
nanoparticles penetrating the skin and causing cellular damage is unsettling,
the effect that nanoparticles may have on embryos further strengthens the
call for stronger regulatory oversight of these materials in cosmetic products
used on a daily basis by millions of people.
B. Cytotoxic, Mutagenic, and Nuclear Effects of Nanoparticles
Studies have demonstrated that nanoparticles are capable of penetrating at
least part of the way through the dermal layers and further tests strongly
suggest their ability to penetrate completely into the underlying tissues.
What nanoparticles do once inside the human body is largely a mystery:
only one study has been published that reports on nanotoxicity in humans
73due to long-term exposure. Most nanotoxicological predictions are
gleaned from in vivo and in vitro laboratory testing on animals and cellular
cultures.
Cytotoxic literally means "cell-killing." 74 Therefore, the cytotoxicity of
nanoparticles is the measure of how deadly they are to various cell types.
One of the primary methods by which nanoparticles cause harm and
eventually death to human cells is through the production of free radicals
75and other ROS. Free radicals are highly reactive molecules that cause
cellular damage by reacting with almost anything around them. 76 These
chemical forms "damage DNA or cell proteins by changing their proper
71. Toshie Tsuchiya et al., Novel harmful effects of[60]fullerene on mouse embryos
in vitro and in vivo, 393 FEBS Letters 139, 139, 141 (1999).
72. Id. at 141.
73. See Song et al., infra note 99.
74. NIH, National Cancer Institute, NCI Dictionary of Cancer Terms, Definition of
cytotoxic, available at http://www.cancer.gov/Templates/dbalpha.aspx?CdrlD=44020
(last visited Oct. 1, 2009).
75. See Nel I, supra note 39, at 623.
76. James Yeagle, Nanotechnology and the FDA, 12 VA. J.L. & TECH. 1, 7(2007).
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functioning. 77  Such ROS damage leads to deterioration in cellular
functions, including, but not limited to, changes in gene expression,
alteration of normal mitochondrial functions, and DNA fragmentation.
78
Research has found that "[o]xidant-mediated DNA damage is one of the key
factors for the induction of apoptosis," 79 a type of programmed cell death
which may be "an important factor in the induction and/or promotion of
carcinogenesis and certain proliferative diseases."80 C60, used in cosmetics,
can generate ROS and, in instances where this occurs in sufficient quantities,
can result in damage to the cellular membrane and cause cell death.81 The
ROS produced by C60 are also the cause of the embryological damage and
death seen in the Japanese study referenced earlier.82  By producing
superoxide anions (ions with a negative charge), which decay into hydrogen
peroxide, the C60 causes cellular lysis (rupture) and growth inhibition.
83
This causes such severe damage that the embryos exposed to such an
environment die.
8 4
Another form of carbon nanoparticle, the single-walled carbon nanotube
(SWNT), is profoundly cytotoxic to macrophages85 due to "increased
77. Id.
78. See Chen & von Mikecz, supra note 42, at 85.
79. See Simonelli et al., supra note 64, at 44.
80. Id.
81. Silvana Fiorito, Carbon Nanoparticles: Benefits and Risks for Human Health, in
NANOTOXICOLOGY 167, 171 (Yuliang Zhao & Hari Singh Nalwa eds., 2007).
82. See Tsuchiya et al., supra note 71, at 141-42.
83. See id. at 142.
84. See id. at 141.
85. Chunhai Fan et al., Toxicology of Carbon Nanomaterials, in NANOTOXICOLOGY
181, 188 (Yuliang Zhao & Hari Singh Nalwa eds., 2007). Macrophages are defined as
"phagocytic cell[s] of the immune system that may be fixed or freely motile, is derived
from a monocyte, functions in the destruction of foreign antigens (as bacteria and
viruses), and serves as an antigen-presenting cell." MERRIAM-WEBSTER'S COLLEGIATE
DICTIONARY 745 (1 1th ed. 2003). Essentially, macrophages seek and destroy invaders in
the body.
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oxidative stress and accumulation of peroxidative products" in these cells.
86
The SWNT's sister particle, the multi-walled carbon nanotube (MWNT), is
cytotoxic not only due to ROS production, but also to their actual physical
effects on cells; MWNTs literally tear and rupture the plasma membranes
found in cells. Finally, nanoparticles of zinc oxide and iron oxide have
"exhibited astonishingly high" levels of toxicity.88 In fact, these particles,
along with MWNTs, are potentially as toxic to humans as asbestos. 89 A
June 2009 study demonstrates that MWNTs may cause chronic
inflammation in the lung tissues in the same manner as asbestos fibers. With
asbestos, this chronic inflammation leads to mesothelioma, making it likely
that MWNTs may result in the same condition. 90 Further, zinc oxide has
been approved for use in sunscreens by the FDA. 9 1 While not considered a
cosmetic, sunscreens are used in cosmetic products to provide a sun
protection factor (SPF). Nano-zinc oxide can result in tissue inflammation,
production of ROS, and lysosomal damage.
92
86. See Fan et al., supra note 85, at 189.
87. Seishiro Hirano et al., Multi-walled Carbon Nanotubes Injure the Plasma
Membrane of Macrophages, 232 TOXICOLOGY & APPLIED PHARMACOLOGY 244, 249
(2008).
88. Tobias Brunner et al., In Vitro Cytotoxicity of Oxide Nanoparticles: Comparison
to Asbestos, Silica, and the Effect of Particle Solubility, 40 ENVTL. Sci. & TECH. 4374,
4379 (2006).
89. C. Poland et al., Carbon Nanotubes Introduced Into The Abdominal Cavity Of
Mice Show Asbestos-Like Pathogenicity In A Pilot Study, 3 NATURE NANOTECHNOLOGY
423-28 (2008); Brunner et al., supra note 88, at 4378.
90. Andre Nel, et al., Understanding the Biophysicochemical Interactions at the
Nano-Bio Interface, 9 NATURE MATERIALS 543, 550 (2009) [hereinafter Nel 11]; see also
NIOSH Science Blog, Persistent Pulmonary Fibrosis, Migration to the Pleura, and Other
Preliminary New Findings after Subchronic Exposure to Multi-Walled Carbon
Nanotubes, http://www.cdc.gov/niosh/blog/nsb03l909_mwcnt.html (March 19, 2009).
For an explanation of mesothelioma, see NIH, NATIONAL CANCER INSTITUTE,
MESOTHELIOMA: QUESTIONS AND ANSWERS, http://www.cancer.gov/cancertopics
/factsheet/Sites-Types/mesothelioma (last visited Oct. 1, 2009).
91. 21 C.F.R. § 352.10 (2000).
92. See Ne II, supra note 90, at 551 tbl. 4, 553.
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Research is still being conducted concerning the mutagenicity of
nanoparticles. However, existing data regarding damage to DNA sequences
in cells indicates a high probability that genetic mutations will occur.
Computer models provide strong evidence that C60 will both bind with and
cause deformations in the DNA structure, preventing the DNA repair
mechanism from working properly.93 This may also result in cancer-causing
genetic mutations. 94  Nano-titanium dioxide, used in cosmetics and
sunscreens for its photoprotective effect, also ironically possesses a
photocatalytic effect, causing the formation of superoxide and hydroxyl
radicals which damage DNA by altering cellular functions and resulting in
mutations that lead to either cellular death or proliferative disorders.9 5
Dependent on ultraviolet (UV) light, the photocatalytic effects of nano-T10 2
can occur within the living layers of skin and could cause damage to many
different types of skin cells at the varying depths to which UV light can
penetrate.
96
Finally, the nuclear effects on cells must be briefly discussed. Although
research is sparse in this area, not all damage to the DNA structures in the
nucleus results in cell death. Studies have demonstrated that certain
nanoparticles, including silicon dioxide (SiO 2), can cause the development
of nuclear aggregates in the nuclei of cells they affect. 9 7 These abnormal
subnuclear structures are present in a variety of neurodegenerative diseases;
however, it is unproven whether nanoparticles can cause such diseases as
Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis
(also known as Lou Gehrig's disease).98
93. Xiongce Zhao et al., C60 Binds to and Deforms Nucleotides, 89 BIOpHYS. J. 3856,
3856 (2005).
94. Viola Ellison & Bruce Stillman, Biochemical Characterization of DNA Damage
Checkpoint Complexes: Clamp Loader and Clamp Complexes with Specificity for 5'
Recessed DNA, 1 PLoS BIOLOGY 231, 231 (2003), available at http:/biology.
plosjoumals.org/archive/1545-7885/1/2/pdf/l 0.1371 joumal.pbio.0000033-S.pdf.
95. See Kiss et al., supra note 33, at 660. A proliferative disorder "is any cellular
disorder in which the cells proliferate more rapidly than normal tissue growth." U.S.
Patent No. 7,374,752 col.7 1.44-45 (filed Aug. 11, 2004).
96. Id.
97. See Chen & von Mikecz, supra note 42, at 89.
98. Id; see also Nel II, supra note 90, at 546.
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C. Yuguo Song, Xue Li and Xuqin Du 's Potentially Groundbreaking Report
on Human Nanotoxicology
On August 20, 2009, a paper written by three Chinese doctors at Beijing
Chaoyang Hospital was published, describing the severe medical conditions
of seven women who were exposed to nanoparticles over an extended period
of time. 99 This paper demonstrates a conclusive link between nanoparticle
exposure and adverse human physiological reactions. The patients in this
case were factory workers in China who were exposed to polyacrylic
nanoparticles with diameters of approximately thirty nm. 10 0 In addition to
serious lung ailments, including pulmonary fibrosis, granulomas, and
hypoxemia (low levels of oxygen in the blood), the patients suffered
intensely itchy rashes on their faces, hands, and forearms. 1 1  Despite
bacteriologic, virologic, and immunologic tests, no clinical correlations
existed between the test results and the condition of the patients.'
0 2
The physiological changes seen as a result of the long-term exposure to
nanoparticles are severe and disturbing. One eighteen-year old patient's
lungs exhibited alterations of the alveolar tissue that resembled emphysema,
while a nineteen-year old patient's lung tissues were in some places
thickened and "hard like a helmet."' 1 3 All patients suffered from excessive
fluid in their lung tissues,' °4 with up to 2,000 milliliters (mL) of fluid
drained from the eighteen year old patient's chest cavity. 10 5 To put this into
perspective, 2,000 mL is equal to two liters, the same amount found in a
bottle of soda in the United States. The nanoparticles were observed to
penetrate into the cells of the lung tissues examined, lodging in the cellular
cytoplasm, nuclei, and other organelles of the cells.' °6 Further, one type of
99. Yuguo Song et al., Exposure to Nanoparticles is Related to Pleural Effusion,
Pulmonary Fibrosis and Granuloma, 34 EUR. RESPIRATORY J. (forthcoming Sept. 2009)
(manuscript at 7, on file with author).
100. Id. (manuscript at 7, on file with author).
101. Id. (manuscript at 7, 13-14, on file with author).
102. Id. (manuscript at 8-9, on file with author).
103. Id. (manuscript at 11, on file with author).
104. Id. (manuscript at 7, on file with author).
105. Song et al., supra note 99, (manuscript at 11, on file with author).
106. Id. (manuscript at 12, on file with author).
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cell examined showed the "characteristic cell morphology of cells
undergoing apoptosis," or cellular death.1"7
The outcomes of the patients in this report are grim. Of the seven
patients, only five survived their nanoparticle-inflicted ordeal.108  The
nineteen-year old patient died of respiratory failure approximately eighteen
months after the initial onset of symptoms, while a twenty-nine-year old
patient died of respiratory failure twenty-one months after her symptoms
began.'0 9 Two of the surviving patients continue to suffer from shortness of
breath, pleural effusions (excess fluid in the space around the lungs), and
slowly progressive pulmonary fibrosis.'
10
After comparing the physiological effects in the patients with those seen
in animal tests and testing all other chemicals in their work environment, the
team notes that the "patients' illness appears to be a 'nanomaterial-related
disease'."' The report concludes by suggesting that when working with
nanoparticles, protection is extremely important.
D. A Brief Overview of Environmental Effects of Nanoparticles
While this Note focuses on the effects of nanoparticles on the human
body, it would be remiss not to include a brief discussion of the adverse
impact nanoparticles can have on the environment. Results from studies of
these environmental effects demonstrate why substances that can be so
harmful to various ecosystems and their resident nonhuman organisms
107. Id.
108. Id. (manuscript at 24 tbl. 1, on file with author).
109. Id. (manuscript at 13, on file with author).
110. Id.
111. Song et al., supra note 99, (manuscript at 14, 17, on file with author).
112. Id. (manuscript at 19, on file with author).
[T]hese cases arouse concern that long term exposure to some nano particles
without protective measures may be related to serious damage to human lungs.
It is impossible to remove nano particles that have penetrated the cell and
lodged in the cytoplasm and caryoplasm of pulmonary epithelial cells, or that
have aggregated around the red blood cell membrane. Effective protective
methods appear to be extremely important ....
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should not be loosely regulated, especially in an industry that produces
products that are applied directly to the human body.
The adverse effects of nanoparticles can be seen more broadly by
reviewing their effects on various parts of the environment and nonhuman
organisms. Nanoparticles have been shown to cause damage to the
ecosystem, beginning with the smallest organisms and moving all the way
up the food chain. The International Center for Technology Assessment
(ICTA) filed a Citizen Petition to the FDA which reveals that "[f]ield tests
have shown that engineered nanoparticles remain active in soil and water for
several weeks and ... can travel in groundwater as far as twenty meters."
113
Due to the damaging effects of nanoparticles on cells in the human body,
particularly macrophages, one report suggests that the same damage could
be done to the simplest of soil organisms. 114 A study in 2005 found that C60
is in fact toxic to soil bacteria even in very low concentrations, though
further studies are needed to confirm this result.1 5 C60 also appeared to be
bactericidal based on the improvement of water quality after the addition of
C60 to the water during a study on the effects of nanoparticles on fish.
116
Further up the food chain, this study also found that the presence of
nanoparticles resulted in brain damage in fish. 117 Largemouth bass exposed
to C60 exhibited significant lipid peroxidation, l l8 damaging the brains of the
fish. 119 In a study of metallic nanoparticle toxicity, researchers discovered
113. CTA Petition, supra note 36, at 30-31.
114. ROYAL SOCIETY, supra note 15, at 45.
115. Press Release, Rice University's Center for Biological and Environmental
Nanotechnology, CBEN: Buckyball aggregates are soluble, antibacterial, (June 22, 2005),
available at http://www.eurekalert.org/pubreleases/2005-06/ru-cba062205.php; but cf
Anders Johansen et al., Effects of C60 Nanoparticles on Soil Bacteria and Protozoans, 27
ENVTL. ToxICOLOGY & CHEMISTRY 1895, 1902 (2008) (concluding that it was not
possible to determine whether soil organisms were affected by the fullerenes or by
something else in the soil samples and suggested that further study was needed to clarify
the ecotoxicology of fullerenes).
116. Eva Oberd6rster, Manufactured Nanomaterials (Fullerenes, C60) Induce
Oxidative Stress in the Brain of Juvenile Largemouth Bass, 112 ENVTL. HEALTH PERSP.
1058, 1061 (2004).
117. See generally id.
118. Id. at 1060.
119. See Fender, supra note 1, at 1069.
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that nano-silver and nano-copper were toxic to all aquatic organisms tested,
which included zebrafish, daphnids, and an algal species. 12  The particles
were especially toxic to the daphnids, invertebrate filter feeding
crustaceans,121 which serve as a food source for fish, birds, and other
crustaceans. 122  Finally, studies have shown that even plant life can be
adversely affected by nanoparticles. Engineered nanoparticles of aluminum
oxide were found to stunt root growth by interacting with the seedlings of
several plant species, including corn, cucumber, cabbage, carrot, and
soybean.
In consideration of the many possible adverse effects, the Royal Society
has recommended that
[u]ntil more is known about the environmental impacts of
nanoparticles and nanotubes, we are keen to manage any potential
risk by avoiding their release into the environment as far as
possible. Therefore, we recommend that factories and research
laboratories treat manufactured nanoparticles and nanotubes as if
they were hazardous, and seek to reduce or remove them from
waste streams.'
24
E. Testing for Nanotoxicological Effects
The potential toxicological effects of nanoparticles on human tissues and
the environment detailed above indicate a serious need for better
nanomaterial testing strategies. The testing methods currently used by the
FDA rely on the macro-scale equivalents to the nanoparticles in question and
thus must be altered to take into account the differences between nanoscale
and macro-scale particles, because
[t]here is a strong likelihood that the biological activity of
nanoparticles will depend on physiochemical parameters not
120. Robert J. Griffitt et al., Effects of Particle Composition and Species on Toxicity
of metallic nanomaterials in Aquatic Organisms, 27 ENVTL. TOXICOLOGY & CHEMISTRY
1972, 1972 (2008).
121. Id. at 1976 tbl.3.
122. Waterflea.org, Introduction, http://www.waterflea.org/waterflea.org/Introduction.
html (last visited Oct. 1, 2009).
123. Study Shows Nanoparticles Could Damage Plant Life, SCIENCE DAILY, Nov. 22,
2005, http://www.sciencedaily.com/releases/2005/11/051122210910.htm.
124. See ROYAL SOCIETY, supra note 15, at 46.
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routinely considered in toxicity screening studies. Physiochemical
properties that may be important in understanding the toxic effects
of test materials include particle size and size distribution,
agglomeration state, shape, crystal structure, chemical
composition, surface area, surface chemistry, surface charge, and
porosity.125
Because of the strong likelihood that the physicochemical properties of
nanoparticles will determine how they act within the body,
any test paradigm must attempt to characterize the test material
with respect to size (surface area, size distribution), chemical
composition (purity, crystallinity, electronic properties, etc.),
surface structure (surface reactivity, surface groups,
inorganic/organic coatings, etc.), solubility, shape and aggregation.
This should be done at the time of [nanomaterial] administration
as well as at the conclusion, if possible.'26
Thus, as new testing methodologies are implemented, they must ensure
that the unique characteristics of nanoparticles are taken into account.
IV. REGULATION OF COSMETICS BY THE FOOD AND DRUG ADMINISTRATION
A. A Brief History of Early Cosmetics Regulation until Passage of the
Federal Food, Drug and Cosmetic Act of 1938
In the United States, responsibility for regulating consumer products
historically fell to the individual states, not the federal government.127 These
traditional roles were recast in January of 1879 when Dr. E. R. Squibb
proposed that the federal government should take action and "the first
comprehensive federal food and drug legislation was introduced in
Congress. ' 28 The first successfully enacted regulatory act, the Federal Food
and Drugs Act of 1906 (1906 Act), did not explicitly include cosmetics
within its regulatory regime.129 However, cosmetics were not completelyunmonitored during the period between 1906 and 1938. The U.S. Postal
125. Oberd6rster I, supra note 55, at Abstract.
126. See Nel I, supra note 39, at 626.
127. See Hutt, supra note 6, at 2.
128. Id.
129. Id. at 5.
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Office enforced mail fraud statutes' to regulate cosmetics until 1914
when 131 the Federal Trade Commission began implementing the provisions
of the Federal Trade Commission Act. While the Postal Office was
relatively lax in its enforcement duties, the FTC brought cases against
cosmetics manufacturers for false or misleading claims.1
33
Soon after the passage of the 1906 Act, the U.S. Department of
Agriculture's Bureau of Chemistry began to advocate for changes in the
legislation.' 34 However, despite the introduction of legislation in 1933 that
encompassed cosmetics, it took five years before the Federal Food, Drug,
and Cosmetic Act of 1938 (the FDCA or Act) was finally signed into law.'
The FDCA defined "cosmetics" to be:
(1) articles intended to be rubbed, poured, sprinkled, or sprayed
on, introduced into, or otherwise applied to the human body or any
part thereof for cleansing, beautifying, promoting attractiveness, or
altering the appearance, and (2) articles intended for use as a
component of any such articles; except that such term shall not
include soap.136
The Act further prohibited the sale of adulterated or misbranded
cosmetics. 13 7 The Act considered a cosmetic adulterated, and consequently
prohibited its sale, if:
130. Hutt, supra note 6, at 5; see generally Federal Food and Drugs Act of 1906, ch.
3915, 34 Stat. 768 (1906); see also 39 U.S.C. § 3005 (2000). For an interesting
discussion of the postal fraud statutes, see generally Frederick M. Hart, The Postal Fraud
Statutes: Their Use andAbuse, 11 FOOD DRUG COSM. L. J. 245 (1956).
131. See Hutt, supra note 6, at 5.
132. Id.; see also 15 U.S.C. §§ 41-58 (2000).
133. See Hutt, supra note 6, at 5.
134. Id. at 6. The Bureau of Chemistry stated in its 1917 Annual Report that is was
"difficult to control injurious cosmetics." Id.
135. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040
(1938), as amended 21 U.S.C. §§ 301-901 (2000). The cosmetic provisions are found in
32 1(i), 361-63.; see also Hutt, supra note 6, at 6-7.
136. 21 U.S.C. § 321(i) (2000).
137. See id. § 331.
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(a) it bears or contains any poisonous or deleterious substance
which may render it injurious to users under the conditions of use
prescribed in the labeling thereof, or, under such conditions of use
as are customary or usual...;..; (b) it consists in whole or in part
of any filthy, putrid, or decomposed substance (c) it has been
prepared, packed, or held under unsanitary conditions whereby it
may have become contaminated with filth, or whereby it may have
been rendered injurious to health; (d) its container is composed, in
whole or part, of any poisonous or deleterious substance which
may render the contents injurious to health; or (e) it is not a hair
dye and it is, or it bears or contains, a color additive which is
unsafe within the meaning of section 379e(a) of this title.
3 8
The Act further provided that a cosmetic is considered misbranded "if its
labeling is false or misleading."' 39 The most notable shortcomings of the
Act resulted from its failure to provide for premarket testing, premarket
notification, or premarket approval. 40  The FDCA provisions relating to
cosmetics have not been amended since 1938, with the exception of the
Color Additive Amendments of 1960, discussed below. 14 1  This is due
primarily to the failure to gain sufficient legislative traction, despite the
efforts of interest groups, government officials, and legislators.
B. The Struggle to Strengthen the FDA's Authority over Cosmetics
1. A Long Litany of Failed Attempts to Expand the FDA's
Regulatory Authority
In 1952, the Delaney Committee, established by Congress to investigate
chemicals in the food supply, "issued a report . . . recommending that
cosmetics be subjected to essentially the same safety requirements as . . .
,,1i42drugs. Ten years later, in March 1962, President Kennedy requested that
138. See id. §§ 361(a)-(e).
139. See id. §§ 362(a)-(e); Congress later provided that a cosmetic was also
misbranded if it failed to comply with regulations issued pursuant to the Poison
Prevention Packaging Act of 1970. See id § 362(t).
140. See Hutt, supra note 6, at 7.
141. See id at 25.
142. See id. (internal quotations omitted).
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cosmetics be subjected to premarket approval. 143  In May of that year,
legislation was introduced into the House of Representatives to comply with
the president's request. 44 Although the FDCA was amended later that year
by the Drug Amendments of 1962,145 premarket authorization authority for
cosmetics was not included; however, it was reintroduced every two years
for the next sixteen years by Representative Leonor Sullivan of Missouri.1
46
Aside from the efforts of Representative Sullivan, many unsuccessful
attempts have been made in Congress to grant the FDA the power to conduct
premarket authorization for cosmetics.
47
In a speech in April of 1969, FDA Commissioner Herbert Ley provided
his support for premarket approval of cosmetics ingredients and asserted that
he believed even the manufacturers who would be affected by such
legislation had come to the conclusion that this would be a positive
occurrence. 4 8  In 1972, legislation was proposed that ultimately met
143. Id.
144. Id.
145. Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1982). It is
interesting to note that the Drug Amendments of 1962 passed unanimously in both
houses of Congress. See 108 CONG. REC. 17422, 22325 (1962).
146. See Hutt, supra note 6, 25. See, e.g., H.R. 1235, 89th Cong., 111 CONG. REC. 89
(1965).
147. See, e.g., H.R. 2244, 83d Cong., 99 CONG. REc. 663 (1953); H.R. 4476, 84th
Cong., 101 CONG. REc. 2255 (1955); H.R. 4015, 85th Cong., 103 CONG. REC. 1224
(1957); H.R. 4431, 85th Cong., 103 CONG. REC. 1574 (1957); H.R. 9153, 85th Cong.,
103 CONG. REC. 13,805 (1957); H.R. 1360, 86th Cong., 105 CONG. REC. 57 (1959); H.R.
5661, 86th Cong., 105 CONG. REc. 4181 (1959); H.R. 1235, 87th Cong., 107 CONG. REC.
61 (1961); H.R. 11582, 87th Cong., 108 CONG. REC. 7753 (1962); H.R. 1235, 88th
Cong., 109 CONG. REc. 56 (1963); H.R. 5777, 88th Cong., 109 CONG. REC. 6865 (1963);
H.R. 6788, 88th Cong., 109 CONG. REc. 10,175 (1963); H.R. 8418, 88th Cong. 109
CONG. REC. 16,932 (1963); H.R. 1235, 89th Cong., 111 CONG. REC. 89 (1965); H.R.
1235, 90th Cong., 113 CONG. REc. 120 (1967); H.R. 4486, 90th Cong., 113 CONG. REC.
2191 (1967).
148. See Hutt, supra note 6, at 26. Ley stated:
It is my impression that the majority, it not all, of the manufacturers who would
be affected by the new legislation have come to the conclusion that it is
desirable to amend the cosmetic section of the Food, Drug and Cosmetic Act.
Certainly we in the Food and Drug Administration see grave deficiencies in the
present system of control. Manufacturers do not have to test their products for
safety before marketing them (though I am told the more responsible firms do
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congressional and presidential approval and became known as the Consumer
Products Safety Act of 1972. Initially, this legislation encompassed
cosmetics and required ingredient labeling and testing for carcinogenicity,
mutagenicity, and teratogenicity. 150 Unfortunately, the legislation was
revised before passage and cosmetics were exempted from the regulatory
provisions; thus, they remained subject only to the FDCA. 1  Once again,
cosmetics fell through the regulatory cracks.
Legislation to expand FDA authority was again introduced in February
152 153 154 1551973, February 1974,15 April 1974, and May 1975. The May 1975
so). Manufacturers may use new chemical in cosmetics without giving any
notice of their use to the Government or to the consumer. Manufacturers are
not required to reveal to any Agency the complaints that they may receive about
a cosmetic that they have placed on the market, and when a bad product goes on
the market, the government is only able to take action to protect the consumer
after it has developed proof of the harm that the cosmetic may cause. This is in
marked contrast to the philosophy underlying the new drug, pesticide chemicals,
food additive and color additive sections of the law. Under these sections it is
the responsibility of the person who wishes to market a new product to prove
that it is safe rather than leaving it to the consumer-user to find that it is unsafe
as a result of injuries that occur after marketing.
Id. Ley is also credited with an unnerving statement in 1969, when he said, "[t]he thing
that bugs me is that people think the F.D.A. is protecting them. It isn't. What the FDA is
doing and what the public thinks it's doing are as different as night and day." Richard D.
Lyons, Ousted F.D.A. Chief Charges 'Pressure' From Drug Industry, N.Y. TIMES, Dec.
30, 1969, atAl.
149. Consumer Products Safety Act of 1972, Pub. L. No. 92-573, 86 Stat. 1207
(1972).
150. See Hutt, supra note 6, at 26. See also S. 3527, 92nd Cong. (1972); 118 CONG.
REc. 14098-14107 (April 25, 1972). A substance is teratogenic if it causes
developmental malformations. See MERRIAM-WEBSTER'S COLLEGIATE DICTIONARY 1289
(11 th ed. 2003).
151. See Hutt, supra note 6, at 26.
152. S. 863, 93rd Cong., 119 CONG. REc. 3194 (Feb. 15, 1973).
153. S. 3012, 93rd Cong., 120 CONG. REC. 3120 (Feb. 18, 1974).
154. H.R. 14009, 93rd Cong., 120 CONG. REC. 9891 (1974).
155. S. 1681, 94th Cong., 121 CONG. REC. 13298 (May 7, 1975).
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legislation, introduced by Senator Thomas Eagleton of Missouri, passed the
Senate with a voice vote, but was not taken up by the House of
Representatives and was not reconsidered in later years. 56 It must be noted
that from 1973 to 1975, the proposed legislation did not contain provisions
to provide for premarket approval of cosmetics. However, it did require
premarket testing and safety substantiation by the manufacturers,
157
something which to this day remains voluntary.
158
In 1978, the Government Accountability Office (GAO) lent its support to
critics of the cosmetic regulatory system with a report titled "Lack of
Authority Hampers Attempts to Increase Cosmetic Safety," which stated that
"[a]lthough there is increasing evidence that some cosmetic products may
carry a significant risk of injury to consumers, the Food and Drug
Administration does not have an effective program for regulating
cosmetics.' ' 159  The report further found that the FDA failed to make
effective use of the authority it did possess by neglecting to inspect most
cosmetic manufacturers' facilities and failing to sample their products to test
for compliance with the FDCA. 16 In 1990, the GAO published a follow-up
report in response to a request from Representative Ron Wyden of Oregon,
who, in 1988, had conducted congressional hearings on strengthening
cosmetic regulation. 16 1 This study pointed out the glaring shortcomings of
the voluntary regulatory system that remains in place and unchanged to this
day. The report found that less than forty percent of the 2,000 to 2,500
cosmetics manufacturers had voluntarily registered with the FDA,' 62 and
only three percent of the 4,000 to 5,000 cosmetics distributors had filed
adverse reaction reports with the FDA.163 Finally, the report noted that not
156. See Hutt, supra note 6, at 27.
157. Id. at 26-27.
158. James T. O'Reilly, FDA, vol. 1, § 17:8, 17-31 (1997).
159. GAO, Lack of Authority Hampers Attempts to Increase Cosmetic Safety, HRD-
78-139, at ii (1978), available at http://archive.gao.gov/f1002a/106839.pdf (last visited
Nov. 7, 2009).
160. Id. at 92.
161. GAO Report 1, supra note 7, at 1.
162. Id. at 3.
163. Id. at 4.
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only did many cosmetics manufacturers lack adequate safety test data, some
even refused to disclose test results.
1 64
The 1990 GAO report strengthened Representative Wyden's belief that
the cosmetic regulatory system needed to be overhauled. In particular, he
was concerned with the "wait-and-watch" approach used by the system.
This is evidenced by his statement that "it's quite clear that there are major
gaps in the safety system. Public health policy should have us get out in
front of these problems, rather than waiting until someone is injured and
then going in after the fact."' 165 Representative Wyden drafted legislation
that "included a pre-market testing requirement; increased FDA access to
safety and consumer complaint data; mandatory registration of
manufacturing establishments, products, and ingredients; and mandatory
ingredient listing for professional products." Unfortunately, that
legislation was never introduced.
167
The next major attempt at overhaul occurred in the early 1990s, 6 in the
wake of the generic drug scandal of the late 1980s. 169 The FDA sought
"broad new administrative power to subpoena industry documents, inspect
company records, impose requirements for the maintenance of records and
the submission of reports, assess civil money penalties, order product recalls,
destroy violative imported articles, and embargo any product for up to thirty
164. Id.
165. Martin Tolchin, Consumer's World; Who's Monitoring Cosmetics Safety, N.Y.
TIMES, Apr. 14, 1990, §1, at 40, available at http://query.nytimes.com/gst/
fullpage.html?res=9COCE2D91 F3EF937A25757COA966958260&sec=&spon=&pagewa
nted=l.
166. Personal Care Products Council, Personal Care Products Council History,
http://www.personalcarecouncil.org/Content/NavigationMenu/About-Us/History/History
5.htm (last visited Sept. 22, 2009).
167. Id.
168. See Hutt, supra note 6, at 28.
169. The generic drug scandal occurred in 1989, when FDA officials were discovered
to have taken bribes to delay the approval of a company's generic drug applications. The
scandal was worsened when it was discovered that the bribes were paid by the company's
competitors. Opinion, The Generic Drug Scandal, N.Y. TIMES, October 2, 1989, at A18,
available at http://query.nytimes.com/gst/fullpage.html?res=950DE6DE 1E38F93 IA3575
3C1A96F948260#; see also Hutt, supra note 6, at 28.
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days."' 70 Due to fierce opposition from the industry'17 and President George
H. W. Bush, the legislation to enact the enforcement changes sought by the
FDA never made it to the floor of either chamber of Congress and was never
reintroduced. 72
2. Two Victories in the Fight to Expand the FDA's Regulatory
Authority
Despite this long line of failures, two federal premarket clearance
requirements for cosmetics were successfully enacted. The first of these
derive from the Color Additive Amendments of 1960 (Amendments).1 73
This statute amended the FDCA to prohibit the use of a color additive unless
the additive was specifically listed in a federal regulation as available for
use.1 74 The Amendments also provided for what is known as the General
Safety Provision, which requires that a petition to use a new color additive
must contain "sufficient data to demonstrate that the color additive is 'safe'
under its intended conditions of use."1 7 5 Furthermore, manufacturers must
substantiate the safety of not only a finished cosmetic product but also each
ingredient used in the product. 76 If a manufacturer fails to provide safety
data to the FDA, then the product will be deemed misbranded unless the
manufacturer places the following warning on the packaging of the product:
"Warning-The safety of this product has not yet been determined."
1 7
170. See Hutt, supra note 6, at 28.
171. See generally Food, Drug, Cosmetic, and Device Enforcement Amendments:
Hearing before the Subcomm. on Health and the Environment of the H. Comm. on
Energy and Commerce, 102nd Cong., 217 (1991); see also Food, Drug, Cosmetic, and
Device Enforcement Authorities Act, Hearing of the S. Comm. on Labor and Human
Resources, 102nd Cong., 143 (1992).
172. See Hutt, supra note 6, at 28.
173. Color Additive Amendment of 1960, Pub. L. No. 86-618, 74 Stat. 397 (1960).
174. Thomas J. Donegan, Jr., Fifty Years of Cosmetic Safety: A Government and
Industry Partnership, 50 FOOD & DRUG L.J. 151, 154 (1995).
175. See Hutt, supra note 6, at 12.
176. 21 C.F.R. § 740.10 (2008).
177. Id.
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The following statement by the FDA accompanied the issuance of the
regulation requiring safety substantiation: "[i]t is not the intention of the
regulation to require the warning statement in circumstances where
reasonable scientific opinion would regard the available data as
adequate."' 178 Scientific studies regarding the safety of nanoparticles remain
inconclusive as to whole-human exposure effects and as a result there can be
no reasonable scientific opinion formed that would regard the existing
nanotoxicological data as adequate to satisfy the regulation. Thus, this
statement in conjunction with the lack of scientific consensus seems to
indicate that with regard to cosmetic products containing nanoparticles, the
FDA must require manufacturers to provide safety substantiation for the
products in question or else deem such products mislabeled, something it
does not in fact do.
In 1974, the FDA successfully implemented a second round of premarket
requirements which compelled manufacturers to provide full ingredient
labeling for cosmetic products. 179 The FDA derived this authority from the
1966 Fair Packaging and Labeling Act.' 80 The regulations promulgated by
the FDA require that ingredients are listed "in descending order of
predominance," meaning that the ingredient with the highest concentration
should be listed first, the ingredient with the next highest concentration
second, and so on. 18' The regulation further provided the method for
determining which chemical name to place on the ingredient labeling for
each chemical ingredient. 82  Unfortunately, the FDA operates on an
assumption of bioequivalence, assuming that nanomaterials are no more
inherently dangerous than their macro-scale counterparts.' As a result,
178. Food, Drug, and Cosmetic Products: Warning Statements, 40 Fed. Reg. 8916
(Mar. 3, 1975) (emphasis added).
179. 21 C.F.R. § 701.3 (2008); Designation of ingredients, 39 Fed. Reg. 10,056-57
(Mar. 15, 1974).
180. Pub. L. No. 89-755, §§ 5, 6, 80 Stat. 1296 (codified at 15 U.S.C. §§ 1454-55
(2000)).
181. 21 C.F.R. § 701.3(a) (2008).
182. §§ 701.3(c)(1)-(4).
183. FDA, FDA Authority Over Cosmetics, http://www.cfsan.fda.gov/-dms/cos-
206.html (last visited Sept. 23, 2009); FDA, Nanotechnology, A Report of the U.S. Food
and Drug Administration Nanotechnology Task Force 11 (2007) [hereinafter Task Force
Report] http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/Nanotechnology
/ucmI 10856.pdf.
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manufacturers need not label nanomaterials on products and may instead list
them under macro-scale materials with the same composition, despite their
radically different characteristics.
C. Overview of FDA 's Current Cosmetics Authority
Premarket approval of any kind by the FDA of cosmetics remains limited
to color additives and not to finished cosmetics or their other ingredients.'
84
In other words, the FDA still has no legal authority to require premarket
safety substantiation of cosmetic products. This hampers its ability to
meaningfully safeguard the American public.'8 5 Further, "[m]anufacturers
are not required to register their cosmetic establishments, file data on
ingredients, or report cosmetic-related injuries to [the] FDA" but are
"encouraged to register their establishments and file Cosmetic Product
Ingredient Statements with the FDA's Voluntary Cosmetic Registration
Program."' 186  The FDA cannot mandate a recall of a cosmetic product
184. John E. Bailey, Organization and Priorities of FDA 's Office of Cosmetics and
Colors, in COSMETIC REGULATION IN A COMPETITIVE ENVIRONMENT 217, 218 (Norman F.
Estrin & James M. Akerson eds., 2000); see also Helen North-Root, Substantiating the
Safety of Cosmetic and Toiletry Products, in COSMETIC REGULATION IN A COMPETITIVE
ENVIRONMENT 279, 286 (Norman F. Estrin & James M. Akerson eds., 2000) ("With the
exception of color additives and the few restricted substances, no hard and fast rules (or,
for the time being, regulations) exist to dictate which ingredients are safe to put into a
cosmetic or toiletry and which finished cosmetic or toiletry products are safe to
market.").
185. Michael R. Taylor, Regulating the Products of Nanotechnology: Does the FDA
Have the Tools It Needs? 51 (Woodrow Wilson Center for Scholars, Project on Emerging
Nanotechnologies 2006), available at http://www.nanotechproject.org/process/assets/files
/2705/1 10_pen5_fda.pdf ("Cosmetics, obviously, comprise the product category for
which the FDA's legal arsenal is most lacking if the agency is to play a meaningful pre-
market oversight role rather than simply react to products and, possibly, problems after
they appear in the marketplace.").
186. See Task Force Report, supra note 183, at iii. The Task Force Report elaborates
that:
[f]or products not subject to premarket authorization by FDA, such as cosmetics
and dietary supplements, the agency generally does not receive data, including
safety data, before the products are marketed. Furthermore, there are no post-
marketing reporting requirements for adverse events associated with cosmetics.
Therefore, FDA receives only cosmetic adverse event reports that are submitted
voluntarily.
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already on the market and may only request that a manufacturer voluntarily
remove a dangerous product from the market. 187  Essentially, cosmetics
manufacturers "may use any ingredient or market any cosmetic until the
FDA demonstrates that it may be harmful-something that rarely occurs."'
88
However, the FDA is not completely impotent. It does possess some
regulatory authority under the FDCA. The FDA has general statutory
authority to conduct inspections of cosmetics companies without providing
prior notice, as long as the inspection occurs at a reasonable time and in a
reasonable manner. Due to the limited fiscal resources allocated to the
FDA, however, cosmetic companies are inspected infrequently. 190  If the
FDA determines that a cosmetics company has violated cosmetics laws and
regulations, it has several remedies at its disposal. It may issue a warning
letter in order to give the company "an opportunity to take voluntary and
prompt corrective action before [the FDA] initiates an enforcement
action."' 191 As stated previously, the FDA cannot mandate a recall, but may
request that the offending company voluntarily recall a product from the
market. 192 If the company persists in violating the laws or regulations in
question, the FDA may file suit in federal court to institute a civil seizure
action, 193 an injunction action,' 94 or a criminal prosecution.195
Id.; see Task Force Report, supra note 183, at 15; see also 21 C.F.R. § 720 (2003)
(providing for the voluntary filing of cosmetic product ingredient composition
statements).
187. 21 C.F.R. §§ 7.40-7.59 (2008) (dealing with FDA recalls generally).
188. See Lin, supra note 33, at 373.
189. 21 U.S.C. § 374(a)(1) (2000).
190. See O'Reilly, supra note 158, at 17-32.
191. FDA, REGULATORY PROCEDURES MANUAL, 4-1 (Mar. 2008), available at
http://www.fda.gov/ora/compliance ref/rpm/pdf/ch4.pdf. The manual further states,
"Warning letters are issued to achieve voluntary compliance and to establish prior
notice." Id.
192. FDAJCFSAN/Office of Cosmetics and Colors, FDA Recall Policy for Cosmetics
(Jul. 29, 2002), http://www.fda.gov/Cosmetics/ProductandlngredientSafety/RecallsAlerts
/ucm173559.htm. See also 21 C.F.R. §§ 7.40-7.59 (providing an overview of the FDA's
role in recall and the manufacturer's responsibilities).
193. 21 U.S.C. § 334 (2000).
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Unfortunately, manufacturers "are willing to take the risk of FDA censure
because the chances of getting caught are slim."' 96 Even if they are caught
engaging in forbidden behavior, "by the time the FDA receives a consumer
complaint, sends off a series of warning letters, or issues a summons for an
injunction, years might have passed. ' 9 7  Currently, manufacturers are
willing to pay fines as a cost of business and continue to engage in the
behavior which instigated the fines.'
98
The FDA has openly acknowledged its weak statutory authority over
cosmetics. Margaret Gilhooley, the FDA's former Associate Chief Counsel
for Food and Cosmetics, noted in 1978 that "[t]he existing law has some
weaknesses . . . , one of them being that the FDA does not have general
authority to obtain manufacturers' records and safety related data."' 99 In its
official magazine, the FDA Consumer, the FDA admitted that "[t]he
regulatory requirements governing the sale of cosmetics are not as stringent
as those that apply to other FDA-regulated products .... [M]anufacturers
may use any ingredient or raw material, except for color additives and a few
prohibited substances, to market a product without a government review or
approval. 200
Knowing the details of the FDA's authority over cosmetics, it is now
important to know how the FDA applies the various regulatory provisions at
its disposal to cosmetic products containing nanoparticles. The FDA's
current position on nanoparticles in cosmetics is also of concern and must be
examined.
194. See generally id. at § 332.
195. See generally id. at §§ 331, 333.
196. Erika Kawalek, Artfully Made-Up, LEGAL AFF. Nov. - Dec. 2005, at 54, 56.
197. Id.
198. Id.
199. Margaret Gilhooley, Federal Regulation of Cosmetics: An Overview, 33 FOOD,
DRUG, COSM. L. J. 231, 232 (1978).
200. Carol Lewis, Clearing Up Cosmetic Confusion, FDA CONSUMER, May/June
1998, available at http://www.pueblo.gsa.gov/cic_text/health/cosmetic-confusion/398
_cosm.html. The article quotes John Bailey, former director of FDA's Office of
Cosmetics and Colors, as saying, "[c]onsumers believe that 'if it's on the market, it can't
hurt me.' And this belief is sometimes wrong." Id.
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V. THE FDA'S DANGEROUS STANCE ON THE USE OF NANOPARTICLES IN
COSMETICS
While the FDA has the ability to regulate in many other areas, "[n]o FDA
regulations or guidances to the industry currently exist that address specific
problems that nanotechnology may present.' 2° 1 The FDA states that it
"believes that the existing battery of pharmacotoxicity tests is probably
adequate for most nanotechnology products that [it] will regulate."20 2 It
further claims that "[p]article size is not the issue. As new toxicological
risks that derive from the new materials and/or new conformations of
existing materials are identified, new tests will be required. 20 3
It is of little comfort to consumers that the laws and regulations under
which the FDA oversees cosmetics were written long before the advent of
nanotechnology. 2°4 Due to the failure of Congress to provide the FDA with
premarket regulatory authority over cosmetics, the FDA cannot mandate that
manufacturers submit data regarding the use of nanoparticles in their
products. 205 This is made clear in the FDA's own report, issued by the
Nanotechnology Task Force, which states that "[w]hen dealing with
products not subject to premarket authorization, the agency has less ability
to obtain information about the presence of nanoscale materials." 20 6 It is of
particular concern that, while the FDA can rigorously regulate drugs and
medical devices, it has no real teeth when it comes to regulating cosmetic
products, which are more likely to contain nanoparticles. 207 As one author
has stated:
201. Eric M. Kraus, It's No Small Matter: FDA Task Force and EPA Weigh In on
Nanotechnology, 24 ANDREWS PHARMACEUTICAL LITIG. REP. 2008 at 13, 14.
202. FDA, FDA Regulation of Nanotechnology Products, available at
http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/NanotechnologyTa
skForce/ucm 115441 .htm (emphasis added) [hereinafter FDA Nanotechnology Webpage].
203. Id.
204. See Task Force Report, supra note 183, at 4.
205. Id. at 30.
206. Id.
207. See Fender, supra note 1, at 1074. ("Some of the most prominent
nanotechnology products on the U.S. market are cosmetics, which make up more than
15% of the nanotechnology-product market.").
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Any doubts expressed about the adequacy of the FDA's regulatory
scheme become even more pressing once one considers that the
FDA has little to no regulatory power over these types of
products-products that, if they contain nanomaterials, present the
same hazards that exist for pharmaceutical or medical device
products.
20 8
The limited resources of the FDA have made it difficult for the agency to
"assess the risks that would derive to the general population from the wide-
scale deployment of nanotechnology products."
20 9
Further damaging for the FDA is a report issued by its own Subcommittee
on Science and Technology, 2 10 which came to three major conclusions about
the FDA's inability to fulfill its mission. First, the report concluded that "the
FDA cannot fulfill its mission because its scientific base has eroded and its
scientific organizational structure is weak. ' '21 This has resulted in the FDA
being unable to keep up with scientific advances, which, in turn, is putting
212the lives of American consumers at risk. The second conclusion of the
report is that the FDA's "scientific workforce does not have sufficient
capacity and capability. ' 213 Inadequately trained scientists take longer to
make decisions and sometimes make the wrong decisions when it comes to
214
regulatory approval or disapproval. The lack of sufficiently trained
employees means that the FDA is unable to respond quickly and effectively
to emerging scientific fields. 2 15 The Subcommittee's third major conclusion
is that the information technology infrastructure of the FDA is inadequate.
216
208. Id.
209. FDA Nanotechnology Webpage, supra note 202.
210. See generally Subcommittee on Science & Technology, FDA SCIENCE AND
MISSION AT RISK (FDA 2007) [hereinafter Subcommittee Report], available at
http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b 02 01 FDA%20Report
%20on%2OScience%20and%20Technology.pdf.
211. See id. at 3.
212. Id.
213. Id. at4.
214. Id. at 5.
215. Id.
216. Id.
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Reports of investigators remain handwritten, much of the FDA's critical data
is stored in warehouses in hard copy with no backup, and the computer
systems frequently fail. 2 17  The report further found that the FDA has
"insufficient capacity in modeling, risk assessment and analysis" and that the
FDA's "science agenda lacks a coherent structure and vision, as well as
effective coordination and prioritization.,
2 18
Aside from the deficiencies pointed out by the Subcommittee's report,
there is a dangerous flaw in the FDA's belief that the current testing methods
for pharmacotoxicity are "probably adequate."2 19 These tests are "based on
and completed regarding bulk material states of many recently engineered
nanoparticles.' 22° This presumption of bioequivalence is a dangerous error.
As seen previously in this Note, 2 1 experts around the world conclusively
and overwhelmingly agree that the unfavorable effects of nanoparticles
cannot be determined by examining the toxicity of the same materials in
their bulk states. 2 The FDA's stance is thus "at odds with all scientific
studies on nanomaterials and their fundamentally unique properties and
risks., 223 Given the uncertainty of the effects on the human environment, it
is reasonable to conclude that the FDA's current method of gauging
nanoparticle safety based on a presumption of bioequivalence cannot
effectively protect the American public and may even be considered grossly
224negligent. Thus, a new regulatory scheme for cosmetics containing
nanoparticles is needed to ensure the safety of the consumers of cosmetic
products.
217. See Subcommittee Report, supra note 210, at 5.
218. Id. at 30, 33.
219. See FDA Nanotechnology Webpage, supra note 202.
220. See CTA Petition, supra note 36, at 19 (emphasis added).
221. See supra Part II.C.2.
222. See CTA Petition, supra note 36, at 19-20.
223. Id. at 36.
224. Id.
The Journal of Contemporary Health Law and Policy Vol. XXVI: 1
VI. A PROPOSAL FOR A NEW COSMETICS REGULATORY SCHEME
Regardless of the method that is adopted to reform the cosmetic
regulatory system, regulators must be mindful that increased regulation does
not interfere with the effective research and development of newer
nanotechnologies. Any regulatory effort that calls for an absolute
moratorium on development and use of nanotechnologies is "implausible in
an American economy determined to harvest on its public research
investments." 225  Nevertheless, the history of cosmetic regulation, the
current regulatory abilities of the FDA, and nanotoxicity studies suggest that
a more effective and bold course of action must be taken in this area.
In order to prevent the unregulated introduction of nanomaterial-
containing cosmetic products into the marketplace, the FDA must return to
the method it used in the 1960s and 1970s: pushing Congress for legislative
reform in the area of cosmetics regulation. 226 The FDA should join and
encourage consumer safety and protection groups to actively lobby Congress
to enact legislation that is substantially similar to the bill introduced in May
1975 by Senator Eagleton, 227 with one minor change. The May 1975
legislation was referred to by FDA Acting Commissioner Sherwin Gardner
as a "reasonable balance between controlling risks and imposing
inappropriate burdens on Govemment and industry." 228 Senator Eagleton
believed this legislation, known as the Cosmetic Safety Amendments of
1975, would be a "step forward" in American consumer safety.
229
Essentially a revised version of previously .proposed amendments to the
225. Brian Wilhelmi, Nanosilver: A Test for Nanotech Regulation, 63 FOOD & DRUG
L.J. 89, 110 (2008).
226. See Hutt, supra note 6, at 27-28.
227. S. 1681, 94th Cong. (1975); 121 CONG. REC. 13,298-302 (1975).
228. See Hutt, supra note 6, at 27.
229. 121 CONG. REC. 13,299 (1975) (statement of Sen. Eagleton)
I believe that this bill represents an important step forward in consumer safety.
I have sought to strike a reasonable balance between the entirely proper desire
of the cosmetic industry to conduct its business with a minimum of Government
regulation, on the one hand, and the compelling need of millions of American
consumers for some measure of protection against cosmetic-related health
hazards on the other.
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FDCA, the new legislation would amend 230 the FDCA as it relates to
cosmetics. 231 This Note thus proposes that the FDA lobby Congress to pass
the Cosmetic Safety Amendments of 2010.
Title I of the bill would "set forth procedures for the safety substantiation
of cosmetics and cosmetic ingredients, placing the burden on manufacturers
of thoroughly testing their products for safety before offering them to the
public. ' 23  While Title I does not impose a blanket requirement that
cosmetics manufacturers submit safety data prior to sale of their products, it
grants the FDA "the authority to require premarket submission of safety test
data when it believes such submission would better protect the safety of
consumers. ' 233  While this provision initially seems to grant the
manufacturers the same ability to withhold safety test data, the FDA would
be empowered to require that any products containing nanoparticles must be
substantiated for safety and that the results of the safety tests must be
submitted to the FDA, thereby protecting the safety of consumers. This
provision provides the FDA with a large loophole through which to require
extensive review of cosmetic products containing nanoparticles before they
reach the market.
Title I further allows the FDA to order additional specific testing of
products234 and "if it finds that a product or ingredient presents a hazard, [it]
can prohibit certain ingredients, prescribe limits of tolerance, require
additional labeling, or ban a cosmetic." 235 Here, Title I includes a provision
through which the FDA can require even further specific testing of products
containing nanoparticles. If the safety data is unsatisfactory, it may impose
restrictions on their use or even ban cosmetic products containing
particularly harmful nanoparticles. Title I grants the FDA a great deal of
authority without mandating constant extensive action on the agency's part.
This ensures that the FDA has the discretion and authority to enforce the
provisions when it believes it is necessary without creating an infeasible
burden on the already overtaxed FDA.
230. 121 CONG. REc. 13,298-302 (1975).
231. 21 U.S.C. §§ 361-364 (2000).
232. 121 CONG. REc. 13,298 (1975).
233. Id.
234. Id.
235. Id.
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Title I of the legislation would require manufacturers to "register with the
FDA, . . . submit formulas of cosmetics products to the FDA, . . . and
forward consumer complaints about adverse reactions to products to the
FDA." '236 This will serve to "codifqy] and make[] mandatory the FDA's
'voluntary compliance program"' established in the early 1970s.237 Further,
Title II expands the FDA's enforcement and inspection power by
authorizing the FDA to administratively detain suspect products for up to
twenty days, similar to the Department of Agriculture's power over food
products. 238 Requiring manufacturers to register with the FDA will allow it
to easily keep track of who and what it is regulating, which will facilitate
and encourage regular inspections of cosmetics manufacturing facilities.
Granting the FDA statutory authority to detain products will eliminate the
need for the agency to seek judicial seizure of suspect products, a deliberate
process that often results in the suspect products being shipped before they
can be seized. 239 Eliminating this wait time will further allow the FDA to
take quick and decisive regulatory action to ensure consumer safety.
Title III requires cosmetics to possess informational, cautionary, and
ingredient labeling. Title IV contains general provisions regarding
cosmetics and, most importantly, it requires the Secretary of the Department
of Health and Human Services, under whose administrative umbrella the
FDA falls,241 to work with the Small Business Administration to recommend
loans for small cosmetics manufacturers. This will help these manufacturers
bear the cost of complying with the new regulations. It seeks to avoid
236. Id.
237. Id.
238. 121 CONG. REC. 13,299 (1975).
239. Id.
240. Id.
241. HHS, About HHS, Agencies in HHS, http://www.hhs.gov/about/index.
html#agencies (last visited Nov. 20, 2008).
242. 121 CONG. REC. 13,299, 13,302 (1975)
The Secretary shall cooperate with the Small Business Administration with
respect to applications... for loans to assist affected small business entities to
comply with requirements under sections 604 and 601(f). The Small Business
Administration shall direct that applications from such small business entities,
regarding proposed additions to or alterations in plants, facilities, or methods of
operations which are designed to enable such entities to comply with such
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imposing an unfair burden upon the industry as a whole by appeasing
smaller industry members who may initially oppose regulatory reform out of
financially motivated fear. Title IV also gives the FDA "substantive
rulemaking power" and establishes the procedures for issuing rules.
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Additionally, Title IV in the original legislation provided for the preemption
of state laws with respect to the labeling of cosmetic products. It stated
that states could petition the Secretary of Health and Human Services for an
exemption from preemption if the state's proposed requirement imposed a
standard higher than the federal standard, was required by "compelling local
conditions," and did not "unduly burden interstate commerce." 245  The
statute should be amended in newly introduced legislation to allow for an
automatic allowance for states whose standards exceed federal levels
without the need to petition the Secretary, provided that the standards meet
the requirements provided in the original legislation. If a state's proposed
standard is lower than that of the federal government, then it would be
preempted by the federal standard.
This legislative fix provided for above kills two problematic birds with
one pragmatic stone. First, the FDA's regulatory authority over cosmetics is
finally strengthened by granting it the authority to demand premarket safety
substantiation. This would not impose too severe a burden on the industry
because financial assistance would be provided to smaller manufacturers.
Second, it alleviates burdens on manufacturers by not requiring them to
endure the rigorous premarket approval process, similar to that required for
the approval and marketing of new drugs, which can take years to complete
and is extremely expensive. 246 By creating a more robust regulatory regime
requirements, small be reviewed by the Secretary. The Secretary shall evaluate
each such application and shall report to the Administrator (or to the bank or
lending institution) within 60 days to determine if such additions or alterations
are appropriate and necessary to assist the applicant to comply with such
requirements and whether he recommend that the loan be granted.
Id.
243. Id. at 13,299.
244. Id.
245. Id. at 13,302.
246. American Institute for Medical and Biological Engineering, FDA and the Drug
Development Process: How the Agency Ensures That Drugs are Safe and Effective,
http://www.aimbe.org/content/index.php?pid=153 (last visited Oct. 18, 2009) ("Today,
the process of bringing a drug to a patient's bedside takes an average of 8.5 years, costs
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for cosmetics, including a substantive rulemaking power, the FDA could
effectively and efficiently adapt its policies to ensure consumer safety. This
is particularly important in light of the ever increasing usage of potentially
harmful nanoparticles in cosmetic products.
VII. CONCLUSION
While the FDA struggles to adapt to the current "nano-reality," more and
more nanoparticle-containing cosmetic products find their way into the
marketplace. Despite positive steps toward achieving the goal of obtaining a
better understanding of nanotechnology, such as establishing the
Nanotechnology Task Force247 and engaging in intemal research to better
understand the characteristics of nanomaterials, 248 "the fact remains that the
FDA is simply not doing enough to address the challenges that it admits
exist.' '249 The FDA must join with citizens' groups and lobby Congress to
obtain the authority necessary to remedy the asymmetric regulatory regime
as it currently stands. While the agency possesses "life or death" authority
over proposed new drugs, it is essentially powerless when it comes to
regulating cosmetics. In light of the fact that one of the greatest sources of
consumer exposure to nanoparticles is cosmetics, 25 which technically fall
under the FDA's regulatory umbrella, the legislation proposed in this Note
would provide the FDA with the needed flexibility to rapidly adapt to this
new reality. By enacting the proposed legislation, Congress would finally
enable the FDA to properly perform its role as the guardian of public health.
about $500 million, and includes a rigorous review by the Food and Drug
Administration.").
247. Press Release, FDA, FDA Forms Internal Nanotechnology Task Force (Aug. 9,
2006), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements
/2006/ucm108707.htm; U.S. Food & Drug Admin., Nanotechnology, http://www.fda.gov
/nanotechnology/.
248. See FDA Nanotechnology FAQs, supra note 18, at § 4.
249. Fender, supra note 1, at 1095.
250. See CTA Petition, supra note 36, at 36.
